Study wrapper · #1352
Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis.
Tavaglione F, Loomba R Cell reports. Medicine. 2026.
DOI: 10.1016/j.xcrm.2026.103023PubMed: 42697203
Editor's note
A timely expert review from a group that includes Rohit Loomba, one of the most cited investigators in fatty liver disease, anchored to trials with histology-assessed endpoints — the strongest evidence standard in this field. As a review it contributes synthesis rather than new data, and it is candid about open questions on therapy duration, tolerability, and variable response. Useful context following semaglutide's MASH approval.
Plain-language abstract
A review of how GLP-1-based drugs fit into the management of MASH-related liver fibrosis, now that semaglutide is one of the first two FDA-approved agents for the disease, summarizing phase 2 and 3 trials that used biopsy-confirmed liver endpoints.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026